G
Guobang Pharma Ltd
SSE:605507
Guobang Pharma Ltd
SSE:605507
Price:
28.56
CNY
-1.35%
Market Closed
Market Cap:
¥16B
Relative Value
The Relative Value of one Guobang Pharma Ltd stock under the Base Case scenario is 23.93 CNY. Compared to the current market price of 28.56 CNY, Guobang Pharma Ltd is Overvalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
23.93
CNY
Overvaluation 16%
G
Multiples Across Competitors
Competitors Multiples
Guobang Pharma Ltd Competitors
Guobang Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
G
|
Guobang Pharma Ltd
SSE:605507
|
16B CNY | 2.7 | 18.3 | 15.5 | 15.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD | 14.7 | 46.5 | 31.3 | 33.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF | 4.8 | 31.1 | 13.1 | 15.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP | 5.5 | 31.6 | 17.4 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF | 5.5 | 22.2 | 13.7 | 17.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD | 4.7 | 16.7 | 10.4 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.3 | 13 | 9.5 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD | 2.4 | 19.5 | 7.3 | 9.7 | |
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR | 2.8 | 15.8 | 8 | 11.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
